Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1973 Mar;26(3):167–174. doi: 10.1136/jcp.26.3.167

The antimycotic activity of 5-fluorocytosine

R J Holt 1, R L Newman 1,1
PMCID: PMC477679  PMID: 4700499

Abstract

5-Fluorocytosine (5 FC) showed marked in vitro activity against nearly all the clinical isolates of Candida and Cryptococcus examined; the required minimal inhibitory concentration was usually below 2 μg/ml and the minimal cidal concentration below 10 μg/ml. The drug had limited activity towards Aspergillus species and dermatophytes. Strains of Candida and other fungi with greatly enhanced resistance were fairly readily obtained by successive cultures on increasingly high concentrations of 5-fluorocytosine.

Serum, urine, and faecal assays of 5 FC were made by a microbiological method on specimens from eight children who received between 100 and 25 mg/kg/day of the drug over several weeks for candidosis of the urinary tract usually associated with congenital anatomical abnormalities. Seven of these cases were successfully treated but in the other the Candida became highly resistant and treatment was discontinued. Serum drug levels ranged up to 30 μg/ml; urine levels were frequently between 200 and 500 μg/ml. No 5 FC was detected in faecal samples.

Sensitivity tests and assays were also made on samples from subjects receiving 5 FC in other hospitals; five had systemic C. albicans infection, the sixth had cryptococcal meningitis. In the latter case levels up to 34 μg/ml were recorded in the cerebrospinal fluid after oral administration, and an investigation was made into the possibility of competitive antagonism by intrathecal cytosine arabinoside given for Hodgkin's disease. The emergence in two other cases of strains of Candida highly resistant to 5 FC is discussed, and it is suggested that careful laboratory monitoring of cases receiving 5 FC must continue throughout therapy and afterwards.

Full text

PDF
171

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cartwright R. Y., Shaldon C., Hall G. H. Urinary candidiasis after renal transplantation. Br Med J. 1972 May 6;2(5809):351–351. doi: 10.1136/bmj.2.5809.351-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Davies R. R., Reeves D. S. 5-fluorocytosine and urinary candidiasis. Br Med J. 1971 Mar 13;1(5749):577–579. doi: 10.1136/bmj.1.5749.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Giege R., Weil J. H. Des tRNA de levure ayant incorporé du 5-fluorouracile provenant de la désamination in vivo de la 5-fluorocytosine. Bull Soc Chim Biol (Paris) 1970 Mar 31;52(2):135–144. [PubMed] [Google Scholar]
  4. Holt R. J., Newman R. L. Candida in the faeces of children receiving oral tetracycline and phenoxymethyl penicillin. J Clin Pathol. 1967 Jan;20(1):80–83. doi: 10.1136/jcp.20.1.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Holt R. J., Newman R. L. Laboratory assessment of the antimycotic drug clotrimazole. J Clin Pathol. 1972 Dec;25(12):1089–1097. doi: 10.1136/jcp.25.12.1089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Holt R. J., Newman R. L. Urinary candidiasis after renal transplantation. Br Med J. 1972 Jun 17;2(5815):714–715. doi: 10.1136/bmj.2.5815.714-d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Holt R. The classification of staphylococci from colonized ventriculo-atrial shunts. J Clin Pathol. 1969 Jul;22(4):475–482. doi: 10.1136/jcp.22.4.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. LIGHTBOWN J. W., SULITZEANU D. The assay of penicillin in blood-serum using Sarcina lutea. Bull World Health Organ. 1957;17(4-5):553–567. [PMC free article] [PubMed] [Google Scholar]
  9. Logan R. L., Goldberg M. J. C. albicans resistance to 5-fluorocytosine. Br Med J. 1972 Aug 26;3(5825):531–531. doi: 10.1136/bmj.3.5825.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Record C. O., Skinner J. M., Sleight P., Speller D. C. Candida endocarditis treated with 5-fluorocytosine. Br Med J. 1971 Jan 30;1(5743):262–264. doi: 10.1136/bmj.1.5743.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Scholer H. J. Chemotherapie von Mykosen der inneren Organe. Schweiz Med Wochenschr. 1968 Apr 20;98(16):602–611. [PubMed] [Google Scholar]
  12. Shadomy S. In vitro studies with 5-fluorocytosine. Appl Microbiol. 1969 Jun;17(6):871–877. doi: 10.1128/am.17.6.871-877.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Utz J. P., Tynes B. S., Shadomy H. J., Duma R. J., Kannan M. M., Mason K. N. 5-Fluorocytosine in human cryptococcosis. Antimicrob Agents Chemother (Bethesda) 1968;8:344–346. doi: 10.1128/AAC.8.3.344. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES